Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
- Status
- COMPLETED
- Phase
- PHASE2
COMbination of Bipolar Androgen Therapy and Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
- Status
- TERMINATED
- Phase
- PHASE2
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2